



VOTRIENT (pazopanib) and generics

#### Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

# Part A - Patient Patient Information

r delone information						
First Name:			Last Name:			
Insurance Carrier Name/Number:						
Group Number:		Client ID:				
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent			
Language: English French			Gender: Male Female			
Address:						
City:		Province:		Postal Code:		
Email address:						
Telephone (home):		Telephone (cell):		Telephone (work):		
Please check any box that applies to the patient:  The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed.  The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.						
Coordination of benefits						
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.					
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A  What is the coverage decision of the drug? Approved Denied *Attach decision letter*					





VOTRIENT (pazopanib) and generics

#### **Authorization**

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





VOTRIENT (pazopanib) and generics

### Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

VOTRIENT (pazopanib) and generics		New red	☐ New request ☐ Renewal request*		
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration	
Site of drug administrati	on:				
Home Physi	cian's office/Private	e Clinic Private Clinic (within Hosp	oital - no public or gov	vernment funding)	
Hospital (inpatient)	Hospital (ou	utpatient)			
Name of the hospital or					
rtaine of the noopital of	private omno.				
Address:					
City: Prov		Province:	Postal code:		
* Please submit proof	of prior coverage if a	available			
•	_	available			
•	_	available			
•	LITY CRITERIA				
SECTION 2 – ELIGIBI  1. Please indicate if the	LITY CRITERIA				
5ECTION 2 - ELIGIBI  1. Please indicate if the Renal Cell Carcinoma	LITY CRITERIA ne patient satisfies t	he below criteria:	logy in an adult. AND		
1. Please indicate if the Renal Cell Carcinoma  For the treatments	LITY CRITERIA  ne patient satisfies t  ent of metastatic ren	he below criteria: nal cell carcinoma (RCC) of clear cell histo	logy in an adult, AND		
1. Please indicate if the Renal Cell Carcinoma  For the treatment of the patient has	LITY CRITERIA  ne patient satisfies the patient of metastatic renewants received no prior systems.	the below criteria:  nal cell carcinoma (RCC) of clear cell histo ystemic therapies, OR			
1. Please indicate if the Renal Cell Carcinoma  For the treatment of the patient has	LITY CRITERIA  ne patient satisfies the patient of metastatic renewants received no prior systems.	he below criteria: nal cell carcinoma (RCC) of clear cell histo			
1. Please indicate if the Renal Cell Carcinoma  For the treatment of the patient has the patient had the patie	LITY CRITERIA  ne patient satisfies the patient of metastatic renewants received no prior systems.	the below criteria:  nal cell carcinoma (RCC) of clear cell histo ystemic therapies, OR			
1. Please indicate if the Renal Cell Carcinoma  For the treatment The patient has The patient has Soft Tissue Sarcoma	LITY CRITERIA  ne patient satisfies the patient satisfies the patient satisfies the patient of metastatic rent of metastatic re	the below criteria:  nal cell carcinoma (RCC) of clear cell histo ystemic therapies, OR			
1. Please indicate if the Renal Cell Carcinoma  For the treatment The patient has The patient has Soft Tissue Sarcoma  For the treatment For the treatment The patient has Soft Tissue Sarcoma	LITY CRITERIA  ne patient satisfies the patient of metastatic renes received no prior sea had an inadequate and of advanced soft	the below criteria:  nal cell carcinoma (RCC) of clear cell histo ystemic therapies, OR e response to prior treatment with cytokine	es for metastatic dise	ease	
1. Please indicate if the Renal Cell Carcinoma  For the treatment The patient has The patient has Soft Tissue Sarcoma  For the treatment The patient has AND	LITY CRITERIA  ne patient satisfies to the patient satisfies to the patient satisfies to the patient of metastatic renewant of metastatic renewant satisfies to the patient of advanced soft and an inadequate satisfies experienced disease	the below criteria:  nal cell carcinoma (RCC) of clear cell histo ystemic therapies, OR e response to prior treatment with cytokine tissue sarcoma (STS) in an adult, AND	es for metastatic dise	ease	
1. Please indicate if the Renal Cell Carcinoma  For the treatment The patient has The patient has Soft Tissue Sarcoma  For the treatment The patient has AND  The patient has AND  The patient has AND	LITY CRITERIA  ne patient satisfies the patient satisfies the patient satisfies the patient of metastatic remains received no prior system and an inadequate sent of advanced soft is experienced disease as received prior chemical patients.	the below criteria:  nal cell carcinoma (RCC) of clear cell histo ystemic therapies, OR e response to prior treatment with cytokine tissue sarcoma (STS) in an adult, AND se progression on or after, or was intolera	es for metastatic dise	ease	





VOTRIENT (pazopanib) and generics

OR  None of the above criteria applies.				
Relevant additional information:				
SECTION 3 - PRESCRIBER INFORMATION				
Physician's Name:				
Address:				
Tel:	Fax:			
License No.:	Specialty:			
Physician Signature:	Date:			

### **SECTION 4 - RESPECTING YOUR PRIVACY**

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at <a href="https://www.sunlife.ca/privacy">www.sunlife.ca/privacy</a> or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





VOTRIENT (pazopanib) and generics

### **SECTION 5 - CONTACT US**

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada  ${\mathbb R}$ 

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 2010 STN Waterloo Waterloo, ON N2J 0A6